Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany

Historically, chronic hepatitis C virus (HCV) infection has been the main cause of liver disease and, thus, a common indication for liver transplantation (LT) in the United States and Europe. The replacement of interferon (IFN) with direct-acting antivirals (DAAs) has dramatically changed the field...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hepatology 2018-10, Vol.69 (4), p.982-984
Main Authors: Herzer, Kerstin, Gerken, Guido, Kroy, Daniela, Tacke, Frank, Plewe, Julius, Eurich, Dennis, Spengler, Ulrich, Strassburg, Christian P., Welker, Martin-Walter, Pischke, Sven, Sterneck, Martina, Mehrabi, Arianeb, Weiss, Karl Heinz, Herber, Adam, Berg, Thomas, Zimmermann, Tim, Galle, Peter R., Heinzow, Hauke, Schmidt, Hartmut, Markova, Antoaneta, Serfert, Yvonne, Manns, Michael P., Zeuzem, Stefan, Wedemeyer, Heiner
Format: Article
Language:English
Subjects:
Antiviral agents
Antiviral drugs
Chronic illnesses
Chronic infection
Hepatitis
Hepatitis C
Interferon
Liver diseases
Liver transplantation
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Historically, chronic hepatitis C virus (HCV) infection has been the main cause of liver disease and, thus, a common indication for liver transplantation (LT) in the United States and Europe. The replacement of interferon (IFN) with direct-acting antivirals (DAAs) has dramatically changed the field of HCV treatment, leading to extraordinary feasibility and efficacy, with sustained virologic response (SVR) rates achievable in >90% of patients in almost all populations.1 Consequently, there is expected to be a decline in LTs related to HCV infection.
ISSN:0168-8278
1600-0641
DOI:10.1016/j.jhep.2018.07.001